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1. Introduction
Metabolomics is a field that involves the study of low mass com-
pounds (i.e., metabolites) that are produced through metabolic 
processes [1, 2]. Metabolites are part of a collection of chemi-
cals known as the “metabolome”, which can include small mole-
cules that are found in cells, tissues, organs, or biological fluids. 
The area of metabolomics is of interest because the identity and 
concentration of metabolites can provide information about cel-
lular activity and can be directly related to processes such as pro-
tein and gene expression [1, 2, 3]. This means that metabolomics 
can provide information on the phenotypes of individuals at the 
molecular level [3]. In addition, the characterization and examina-
tion of metabolites could lead to new discoveries in biomedical re-
search and personalized medicine [1, 3].
Research in metabolomics began in the late 1990s and early 
2000s, with the emphasis at that time being on the effects of dif-
ferent metabolites on the gene expression of bacteria and yeast 
[1]. The first examples of metabolomic studies utilized two-di-
mensional thin-layer chromatographic separations to character-
ize metabolites in samples. This provided researchers with evi-
dence that variation in the concentrations of metabolites can 
affect cellular activity [1, 4, 5, 6]. Further progress in the area of 
analytical methods such as structural characterization and sepa-
ration methods has resulted in the development of new instru-
ments and techniques that can be used to provide high resolu-
tion information and data from complex samples such as tissues 
and cells [1, 2].
Research in metabolomics can involve either targeted or un-
targeted approaches [7]. In a targeted approach, researchers use 
techniques such as nuclear magnetic resonance (NMR) spectros-
copy and mass spectrometry (MS) for the identification, quanti-
fication, and structural characterization of specific metabolites. 
This information can be used to examine specific classes of me-
tabolites and to provide information on the biochemical pathways 
that are involved in metabolism [2]. In an untargeted approach, 
scientists use global profiling to analyze the group of chemicals in 
a metabolome as a whole. This second approach is less specific and 
sensitive than the targeted approach but allows for the highest 
possible coverage of the metabolites that may be involved in bio-
chemical pathways [7].
A significant amount of recent research has been devoted to 
metabolic profiling, or the identification and measurement of the 
different metabolites that are present and produced in the metab-
olome [8]. However, it is also important to consider the interac-
tions that occur between metabolites and biological agents, such 
as the binding of cofactors to enzymes, hormones to receptors, 
and drugs or their metabolites to proteins [8]. Information on 
these interactions can be combined with structural data to pro-
vide a better understanding of the regulatory networks and con-
nections in biological pathways. Such information, in turn, could 
provide a better understanding of how healthy and disease states 
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differ at the molecular level and could provide vital data that can 
be used for pharmaceutical development [7, 9].
This review will look at previous studies that have examined 
biological interactions as related to metabolites and proteins as 
binding agents. This will include an overview of the various meth-
ods and techniques that have been used in this work to study me-
tabolite–protein interactions. A summary will also be provided 
of the different types of metabolite–protein binding interactions 
that have been investigated with these approaches. In addition, 
the possible effects that metabolic diseases may have on these in-
teractions will be considered.
2. Techniques for examining metabolite–protein 
interactions
The characterization of metabolite–protein interactions can pro-
vide a better understanding in clinical diagnostics of the cellular 
activity and the biochemical pathways that are present in various 
medical conditions [1–3, 9]. There are many methods that can be 
used to examine the binding of metabolites with proteins. These 
methods may involve the direct examination of binding that oc-
curs between proteins and low mass drugs, hormones and their 
metabolites, or may involve an examination of the free concentra-
tions of these molecules [9–12]. The approaches that are used for 
this purpose can be divided into three categories: in vitro, in vivo 
and in silico techniques [9, 11–46].
2.1. In vitro methods for studying metabolite–protein 
interactions
In vitro methods are the most popular techniques used to character-
ize metabolite–protein interactions. This approach involves the use 
of standard, well-controlled conditions and reagents that are used 
in the laboratory to mimic conditions seen in biological systems. To 
examine metabolite–protein interactions, in vitro methods may use 
a binding assay (e.g., one based on ultrafiltration or equilibrium di-
alysis) to examine an interaction or to identify the chemicals that 
are involved in this process [9]. This approach can provide infor-
mation such as the strength of the interaction, as well as the ther-
modynamics and kinetics of binding and possible conformational 
changes that occur as a result of the interaction [13–15]. Alterna-
tively, an in vitro study may make use of a method that directly ex-
amines the structure of a protein and a bound metabolite, such as 
occurs in X-ray crystallography or NMR spectroscopy [1, 16–20]. 
Other methods may examine the protein–metabolite complex, as 
demonstrated with mass spectrometry [24–29].
There are many in vitro approaches that can be used to examine 
the binding of proteins with small molecules and their metabolites. 
For instance, radiometry and fluorimetry can be used with a bind-
ing assay by employing labeled metabolites that contain either a ra-
dioisotopic label or fluorophore, respectively [10, 21–23]. These la-
beled metabolites are then incubated with proteins and the signal 
that is produced from the label is measured, such as through a dis-
placement assay or a proteome microarray [10, 23]. Radioisotopic 
labeling has been applied to enzymes to determine their activity in 
metabolomic reactions [9]. One example involved the screening of 
potential inhibitors for an enzyme, in which the substrate was ra-
dioactively labeled and the resulting metabolite profiles were ana-
lyzed and measured [21]. Fluorescence labeling can provide similar 
results to radiolabeling; however, this method can also be used to 
identify and determine the location of a binding site for a metabo-
lite on a protein, such as by observing the displacement of specific 
probes that are bound to known locations on a protein [10].
Surface plasmon resonance (SPR) and calorimetry are two 
other methods that can provide information on the strength of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
protein–metabolite binding and the thermodynamics or kinetics 
of this interaction [13–15]. Studies based on SPR utilize an im-
mobilized protein on a sensor chip, in which changes in the reso-
nance energy (e.g., from binding of the protein with a target) are 
detected [9]. The change in this signal is related to the mass of the 
bound metabolites and can be used to determine the equilibrium 
constants for this process or, if examined over time, the associa-
tion and dissociation kinetics that occur between the metabolite 
and protein during binding [9]. The reaction between a metabo-
lite and protein can result in heat being absorbed or given off [9, 
13]. Calorimetry can then be used to measure the overall enthalpy 
of the binding reaction between a metabolite and a protein [13].
NMR spectroscopy and X-ray crystallography are two tools 
that have been used to characterize the structures of metabolite–
protein complexes [9, 16–20]. NMR spectroscopy has often been 
used in recent years for characterizing and identifying metabo-
lites in biological samples, but this method can also be used to ex-
amine conformational changes that occur during the binding of 
metabolites with proteins [18–20]. X-Ray crystallography can also 
give structural information on such interactions by providing de-
tailed information on the binding sites and active sites for hor-
mones, drugs and their metabolites or related compounds on pro-
teins and enzymes [16, 17], as is illustrated in Figure 1 [30].
Mass spectrometry can not only be used as a tool for analyzing 
the structure and identity of metabolites, but it can be used to an-
alyze metabolite–protein interactions in which information about 
enzymatic processes or binding by small molecules is generated 
[9]. Experiments utilizing various types of mass spectrometry, 
such as quadrupole mass spectrometry or matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS), have allowed for monitoring of the resulting products 
and analysis of the reaction kinetics of enzyme-substrate reac-
tions [7, 24, 25]. Further analysis through high resolution mass 
spectrometers (e.g., an orbitrap or Fourier transform ion cyclo-
tron resonance mass spectrometry) has resulted in accurate anal-
yses of enzymatic activities in which the intermediate steps in en-
zymatic reactions can be identified [26–29].
Various separation techniques can also be used to examine 
metabolite–protein interactions. Examples of traditional meth-
ods that have often been utilized for this purpose are equilibrium 
Figure 1. Crystal structure for the complex of human androgen receptor li-
gand-binding domain with testosterone (Testo). Reproduced with permis-
sion from Reference [30].
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dialysis, ultrafiltration, and ultracentrifugation [9, 31–33]. Equi-
librium dialysis and ultrafiltration can both be used to separate 
protein-bound metabolites from free metabolites through the use 
of a semipermeable membrane. These methods are commonly ap-
plied to binding studies to determine the affinity of proteins with 
drugs and small solutes but can be employed in the same way to 
examine the interactions of metabolites with proteins [31]. Ul-
tracentrifugation can be used to provide a similar separation of 
free and protein-bound forms of a metabolite by utilizing a grav-
itational field in combination with a density gradient to separate 
these fractions [9, 32]. However, each of these methods does have 
limitations, such as difficulty in detecting small free solute frac-
tions, undesirable adsorption of solutes onto the membrane (e.g., 
in ultrafiltration or equilibrium dialysis) or overestimation of the 
free fraction due to release of the bound solute during the separa-
tion process [33].
Various chromatographic techniques have also been employed 
to separate free and protein-bound metabolite fractions [34]. As 
an example, size exclusion chromatography (SEC) can be applied 
to this type of analysis when metabolite–protein complexes and 
free metabolites have a sufficiently large difference in size. In this 
type of study, metabolites or small molecules are incubated with a 
protein, and SEC can be used to remove the small molecules from 
proteins [34]. Such a method can be used for either the isolation 
and preparation of metabolite–protein complexes, which can later 
be analyzed by other methods, or can be used in binding studies 
to provide information on the association equilibrium constant 
for a metabolite–protein interaction [8, 34, 35].
Affinity chromatography and high-performance affinity chro-
matography (HPAC) have also become popular for analyzing sol-
ute–protein interactions [35–38]. These affinity methods have an 
immobilized biological molecule, such as a protein, as the station-
ary phase. When used in a low-performance setting, affinity chro-
matography can be used in a similar way as SEC in that it can be 
used for preparation and purification. The use of more rigid and 
efficient supports in HPAC allows this approach to be used as a 
rapid and relatively high-throughput method for providing in-
formation about solute–protein interactions. This information 
can include data on the affinity, thermodynamics and kinetics of 
these processes, as well as information on the types of sites that 
are involved in the interaction (see Figure 2) [35–39].
Capillary electrophoresis (CE) is another separation method 
that can be used to examine metabolite–protein binding [9, 37, 
40, 41]. One way this method can be used is to separate the free 
and bound metabolites through the differences in their size-to-
charge ratios. This approach can be utilized alone to determine 
the affinity of metabolite–protein binding or combined with other 
methods such as mass spectrometry to examine this interaction 
[41]. One form of CE is affinity capillary electrophoresis (ACE), 
in which a biological molecule such as a protein is used as a run-
ning buffer additive, thus making it possible to obtain data on the 
interactions of solute components with this additive [40]. Like 
HPAC, ACE is a relatively fast method and can be used with small 
amounts of sample for the screening or analysis of metabolite–
protein interactions [38, 40].
2.2. In vivo methods for studying metabolite–protein 
interactions
Although in vitro methods can provide detailed information about 
metabolite–protein interactions, in vivo analysis can provide a 
better representation about the metabolite–protein interactions 
within a biological sample [8, 9]. This is particularly true in a sit-
uation where a protein may undergo post-translational modifica-
tions that result in changes in the protein’s interactions with sol-
utes such as drugs and their metabolites [9]. In vivo methods are 
often similar to techniques used for in vitro studies but must be 
able to work with complex samples. In many cases, clinical sam-
ples from patients can be obtained and analyzed through ap-
proaches such as labeling, NMR or MS structural characterization, 
and affinity separation methods. By utilizing in vivo studies, re-
searchers are better able to understand the effect of disease states 
on metabolite–protein interactions, as well as related biochemical 
pathways and regulatory processes [9, 39].
2.3. In silico methods for studying metabolite–protein 
interactions
Another area of examining metabolite–protein interactions is 
through in silico tools [9]. These methods utilize computational 
schemes to determine the docking configurations of a metabolite’s 
binding sites on proteins or enzymes, as obtained through the use 
of molecular modeling or quantum mechanics [42, 43]. This ap-
proach can provide information about the structure of a metabo-
lite–protein complex at a given binding site through an analysis of 
the most thermodynamically favorable configurations. These com-
putational methods can result in docking predictions that have a 
1.5–2 Å accuracy with success rates of 70–80% [43]. If the location 
of a binding site is not known in advance, a homology method can 
be used to predict binding sites on a protein through the use of the 
protein’s amino acid sequence and chemical structures of the me-
tabolites [44]. This method can allow for accurate prediction of li-
gand-binding proteins and enable the development of a database 
for these peptide sequences selected for binding to different metab-
olites [9, 45]. These in silico methods can be combined with in vitro 
analysis to optimize the structural characterization of metabolite–
protein interactions, as demonstrated in NMR experiments [46].
3. Interactions of proteins with hormones and related 
metabolites
Hormones are chemicals that are secreted by endocrine glands. 
Hormones play a significant role in many regulation pathways, 
including metabolism, growth and development [47, 48]. Exam-
ples of low mass hormones include various types of steroids (e.g., 
estrogens and testosterone) or thyroid hormones (e.g., thyrox-
ine) [49–52]. As these chemicals enter the circulation, they are 
Figure 2.  Example of a competition study using high-performance affin-
ity chromatography to examine the interactions of an injected site-selec-
tive probe with a solute that is present at a known concentration in the mo-
bile phase. This example shows the change in the retention factor (k) that 
was measured for R-warfarin as a probe for Sudlow site I of human serum 
albumin (HSA) in the presence of various concentrations of tolbutamide as 
a competing agent. These results were obtained for columns that contained 
two clinical samples of HSA that had different levels of modification due to 
glycation. Adapted with permission from Reference [39].
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carried to their target tissue or organ to produce an effect. Many 
low mass hormones are transported in the bloodstream through 
their binding to serum proteins [51, 52]. These transport proteins 
may bind to a broad range of hormones and other targets, as oc-
curs for human serum albumin (HSA), or they may be specific for 
a given hormone or group of hormones, as is the case for thyrox-
ine-binding globulin (TBG) [49]. Once it has been delivered to its 
target tissue or organ, the hormone can then bind with a receptor 
to produce an effect. This section will consider interaction stud-
ies that have been reported for several types of hormones or their 
metabolites with serum proteins and hormone receptors.
3.1. Thyroid hormones
Thyroid hormones are a group of iodothyronine compounds that 
are responsible for metabolism, growth, development, and the 
regulation of iodine within the body [47]. Many of these hor-
mones are bound in the bloodstream to both HSA through low-
to-moderate affinity interactions and to transthyretin or TBG 
through higher affinity processes [48, 49]. An important com-
pound in this group is the hormone l-thyroxine (l-3,5,3′,5′-
tetraiodothyronine, or T4), which can be metabolized to form 
l-3,5,3′-triiodothyronine (T3) [53, 54]. Both T4 and T3 are actively 
involved in regulatory processes and are more than 99% bound to 
transport proteins in blood [49, 53, 54].
Several studies have explored the structural differences be-
tween thyroid hormones and related compounds as they bind to 
serum proteins or cell surface receptors [53–55]. One report uti-
lized HPAC to characterize the binding of T4, T3 and related com-
pounds with HSA; the results were used to examine both the 
affinity constants and thermodynamic properties of these com-
pounds in their interactions with this protein [54]. Some typical 
results that were obtained in competition studies and through the 
use of site-specific probes are provided in Table 1. The results in-
dicated that these thyroid hormones were interacting with HSA at 
both of the major drug-binding sites on this protein (i.e., Sudlow 
sites I and II) [53, 54]. A comparison of the data obtained for the 
thyroid hormones and their metabolites indicated that the num-
ber and position of iodines, the phenol group, and the thyronine 
backbone were all important during the binding of these com-
pounds to HSA [54]. Structural studies have also been carried out 
through the use of modeling and crystallographic data to examine 
the binding of thyroxine and related compounds to a cell surface 
receptor for thyroid hormones on αvβ3 integrin [55].
3.2. Steroid hormones
The protein binding of steroid hormones and their metabolites 
has also been characterized through a variety of techniques. As 
an example, the crystal structure of the serum transport protein 
sex-hormone binding globulin (SHBG) was determined for a com-
plex of this protein with 5α-dihydrotestosterone [56]. SHBG is an 
important binding agent in blood for many sex hormones and re-
lated compounds, including estradiol, testosterone, androste-5-
ene-3β,17β-diol, and 5α-dihydrotestosterone [47, 49, 56]. The 
information that was obtained from the crystal structure for the 
5α-dihydrotestosterone/SHBG complex was compared with the 
results of previous binding studies for steroid hormones with 
SHBG [57, 58], and this allowed a model of the binding site for 
these compounds to be developed. This model gave good agree-
ment with prior data from site-directed mutagenesis [59–61] and 
photolabeling experiments [62, 63] that have been conducted 
with SHBG [58].
Another structural study looked at the interactions between 
the human androgen receptor (AR) ligand-binding domain and 
several androgen-related steroid hormones and metabolites [30]. 
The compounds that were examined included testosterone, dihy-
drotestosterone, and tetrahydrogestrinone. An example of some 
of the results was provided earlier in Figure 1. Both the binding 
affinity and structural characteristics for the complexes of these 
agents with AR were explored. Tetrahydrogestrinone was found to 
have the highest affinity for the AR ligand-binding domain. This 
strong binding was thought to be due to the presence of greater 
van der Waals interactions for this compound than for the other 
steroids that were studied. Dihydrotestosterone had a higher af-
finity than testosterone, an effect that was proposed to be due to 
the stronger electrostatic interactions between the structure of 
dihydrotestosterone and the AR binding domain [30].
4. Interactions of proteins with fatty acids and related 
metabolites
Fatty acids can also have significant binding to proteins. These 
compounds are carboxylic acids that contain hydrocarbon chains 
with lengths of 4 to 36 carbons. In some fatty acids, the hydro-
carbon chain is unbranched and fully saturated, such as myris-
tic acid (C14:0). In others, the chain contains one or more double 
bonds, as is the case for linoleic acid (C18:2) [48]. Long chain fatty 
acids (i.e., fatty acids with chains containing 16–20 carbons) are 
Table 1. Site-specific association equilibrium constants (Ka) for thyroxine and related compounds with HSA at 37 °C. 
a
                                                                                            Ka (M
−1 × 105) a
Compound                                                 R3               R5                     R3′                 R5′                     Chiral form                           Sudlow site I                                 Sudlow site II
Thyroxine (T4) I I I I L-T4
b 1.4 (±0.1) 5.7 (±0.8)
     D-T4 5.5 (±0.9) 29. (±2)
Triidothyronine (T3) I I I H L-T3 0.170 (±0.001) 0.25 (±0.02)
     D-T3 1.45 (±0.06) 1.2 (±0.2)
Reverse triiodothyronine (rT3) I H I I L-rT3 1.99 (±0.07) 3.3 (±0.6)
Diiodothyronine (T2) I I H H L-T2 0.63 (±0.03) 1.16 (±0.06)
Thyronine (T0) H H H H L-T0 0.18 (±0.02) –
a. Each value in parentheses represents a range of ±1 S.D. All association equilibrium constants were measured at 37 °C and pH 7.4. The data shown in this ta-
ble was obtained from Refs. [53, 54]. Sudlow site I and Sudlow site II are also known as the warfarin site and indole site, respectively.
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particularly critical for a diverse set of cellular and metabolic func-
tions. For instance, long chain fatty acids act as fuel that can be 
stored as triacylglycerols (or triglycerides) and that can be used 
to generate ATP through β-oxidation in mitochondria and peroxi-
somes. In addition, fatty acids are the precursors of phospholipids 
and glycolipids, which are needed for the construction of mem-
branes [64].
Long chain fatty acids such as oleic (C18:1), palmitic (C16:0), 
linoleic (C18:2), stearic (C18:0), arachidonic (C20:4) and palmitoleic 
(C16:1) acid are crucial intermediates in lipid metabolism [65]. 
They tend to have low solubility in water and are typically bound 
in plasma to proteins, with less than 0.1% being present as non-
bound, or “free”, fatty acids. Most of the long chain fatty acids in 
the blood are transported by HSA [65–68]. HSA carries between 
0.1 and 2 mol of fatty acids under normal physiological conditions. 
However, this value can rise to as high as 6 mol fatty acid per mol of 
HSA in the peripheral vasculature during fasting or exercise or dis-
ease states such as diabetes, liver and cardiovascular disease [67].
Many recent studies have attempted to locate fatty acid bind-
ing sites on HSA by using X-ray crystallography or NMR spectros-
copy [67, 69–73]. Some typical results of such studies are pro-
vided in Figure 3 [74, 75]. In addition, site-directed mutagenesis 
has been utilized with these methods to see how specific changes 
in the peptide sequence of HSA will affect its binding proper-
ties and structure [67, 69]. Such studies have revealed that five 
to seven binding sites on HSA may be occupied by medium and 
long chain fatty acids [71]. These binding sites are asymmetrically 
distributed across the three domains of HSA, with three of these 
sites overlapping Sudlow sites I and II [70]. All of these sites have 
similar structural interactions with fatty acids, providing a deep 
hydrophobic pocket for the methylene tail and containing two or 
three polar surface residues nearby which provide a binding loca-
tion for the carboxylic head group of the fatty acid.
A variety of techniques have been employed to estimate the 
binding constants for fatty acids at their sites on HSA. The stron-
gest of these interactions have association equilibrium constants 
that range from 105 and 108 M−1[66, 74–77]. It has been observed 
for fatty acids with multiple binding sites on HSA that the value 
of the individual association constants for each mole of added 
fatty acid increases as the length of the fatty acid chain was raised 
[71]. It was later found that the association equilibrium constant 
for the first bound fatty acid increases with chain length but that 
this increase does not necessarily occur in a linear fashion; in-
stead, the affinity is generally dependent on the hydrophobic por-
tion of the fatty acid and how it interacts with HSA [69]. It has 
further been demonstrated that some fatty acids can have direct 
competition with drugs on HSA or can lead to allosteric effects 
during these binding processes [72, 74, 75, 78].
5. Interactions of proteins with drugs and related 
metabolites
Numerous studies have examined the interactions of drugs and 
their metabolites with proteins. Like low mass hormones, many 
drugs and their metabolites are transported throughout the body 
through the use of serum transport proteins. Approximately 43% 
of the 1500 most commonly used pharmaceutics have at least 90% 
binding to such binding agents [35, 79]. These interactions usu-
ally involve proteins that can bind to a broad range of targets, such 
as HSA and alpha1-acid glycoprotein (AGP), and can play a signifi-
cant role in determining the activity, distribution, rate of excretion 
or metabolism, and toxicity of many pharmaceutical agents in the 
body [80]. In recent years there has also been interest in how the 
presence of drug metabolites can affect the distribution, apparent 
activity, and protein interactions of the parent drug [81].
5.1. General effects of metabolites on drug–protein 
interactions
Many studies have investigated the difference between drugs and 
their metabolites in their overall binding in serum or to specific 
serum proteins. For instance, equilibrium dialysis was used to ex-
amine the binding of propisomide and its major metabolite to 
human serum and isolated serum proteins such as AGP [82] and 
the binding of acetohexamide and its metabolite (−)-hydroxyhex-
amide to HSA [83]. Another study utilized a similar approach to 
investigate the binding by tolterodine and its 5-hydroxymethyl or 
N-dealkylated metabolites to human serum, HSA and AGP [84]. 
Equilibrium dialysis was further used to measure the binding of 
tizoxanide, an active metabolite of the drug nitazoxanide, with al-
bumin and AGP [85].
A few studies have been conducted to provide a more de-
tailed comparison of the binding regions and binding constants 
for drugs and their metabolites on serum proteins. As an exam-
ple, HPAC and competition studies have been used to compare 
the binding regions on HSA for the drug phenytoin and its two 
major metabolites: 5-(3-hydroxyphenyl)-5-phenylhydantoin and 
5-(4-hydroxyphenyl)-5-phenylhydantoin (i.e., m-HPPH and p-
HPPH, respectively) [81, 86]. In an examination of both the ma-
jor and minor drug binding regions of HSA, phenytoin was found 
to have direct binding at Sudlow site II and the digitoxin site, with 
association equilibrium constants at these regions in the range of 
0.65–1.04 × 104 M−1 at 37 °C and pH 7.4 (see Table 2). The same 
drug had allosteric effects plus possible direct binding at Sudlow 
site I and the tamoxifen site [86]. However, m-HPPH and p-HPPH 
only had significant interactions with Sudlow site II, with binding 
constants of 0.32–0.57 × 103 M−1 for this region [81]. Thus, the 
parent drug and its metabolites not only had different affinities 
for HSA but also had differences in the number of their interac-
tion sites with this protein [81, 86].
5.2. Effects of chirality on drug metabolite–protein binding
Another factor to consider for drug- and drug metabolite–pro-
tein binding is the effect of chirality on these interactions. Chiral 
drugs have been estimated to represent 40–50% of all drugs that 
are currently on the market [87, 88]. The separate chiral forms for 
some drugs can exhibit a wide variation in their toxicology, phar-
macokinetics and metabolism. In the extreme case, one enantio-
Figure 3.  Structure of HSA, showing the regions that bind palmitic 
acid. This structure was generated using Protein Data Bank (PDB) file 
ID: 1E7H [75] and is adapted with permission from Reference [74].
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mer may produce the desired function in treatment while another 
may be inactive or even produce undesired or toxic effects. This 
is because within the body numerous compounds (i.e., enzymes, 
plasma proteins, and other biomolecules) work as chiral selectors, 
causing them to sometimes bind or metabolize each chiral form of 
a drug differently [89–95].
These differences have made it possible in the past to use pro-
tein-based HPLC columns, such as those containing serum pro-
teins, for separating the various chiral forms of many drugs [93–
95]. The same approach has been utilized to separate and measure 
chiral drugs and their metabolites in biological samples. For in-
stance, an AGP column was recently used with fluorescence detec-
tion to measure the enantiomers of tramadol and its two major 
metabolites, O-desmethyltramadol and N-desmethyltramadol, in 
plasma samples (see Figure 4). This method was then used to ex-
amine the pharmacokinetics for each of these compounds in the 
body [96]. A similar approach has been used with LC-MS to ex-
amine the chiral forms of methadone and its metabolites 2-eth-
ylidene-1,5-dimethyl-3,3-diphenylpyrrolidine and 2-ethyl-
5-methyl-3,3-diphenyl-1-pyrroline in hair samples from patients 
undergoing methadone maintenance therapy [97].
As has been observed for their parent drugs, the different 
forms of a chiral metabolite can differ in how they interact with 
proteins. One report compared the chiral forms of oxybutynin 
and its metabolite, N-desethyloxybutynin, in their binding and 
competition on HSA and AGP. The results showed that the affin-
ity of oxybutynin enantiomers on AGP was much higher than on 
HSA, and that the enantiomers of N-desethyloxybutynin and oxy-
butynin were all bound by the same site on AGP [33]. Another 
study involving the phenytoin metabolites m-HPPH and p-HPPH 
compared the dissociation rates of the chiral forms of these me-
tabolites from an HPLC column containing immobilized HSA 
[98]. Dissociation rate constants of 8.2–9.6 s−1 were obtained at 
pH 7.4 and 37° C for the enantiomers of m-HPPH, while values of 
3.2–4.1 s−1 were obtained for the enantiomers of p-HPPH. These 
results were then used along with separate estimates of the asso-
ciation equilibrium constants to also compare the association rate 
constants for these metabolites and their enantiomers [98].
5.3. Use of binding data to characterize protein interaction 
sites for drug metabolites
A number of reports have used binding data for drugs, their me-
tabolites and related analogs to learn about the binding sites of 
these compounds on a protein. Binding and retention data that 
have been acquired by HPAC have been used to examine the bind-
ing of several types of compounds with immobilized serum pro-
teins. This approach has been used to examine the binding of war-
farin and coumarin compounds to HSA [99–101], as well as the 
Table 2. Association equilibrium constants (Ka) and types of binding for phenytoin and its metabolites to various regions on HSA. 
a
Binding region on HSA Drug or drug metabolite
 Phenytoin m-HPPH p-HPPH
   
Sudlow site Ib Allosteric effects + possible direct binding No binding No binding
Sudlow site IIb Direct binding Direct binding Direct binding
 Ka = 1.04 × 10
3 M−1 Ka = 3.2 × 10
3 M−1 Ka = 5.7 × 10
3 M−1
Digitoxin site Direct binding No binding No binding
 Ka = 6.5 × 10
3 M−1  
Tamoxifen site Allosteric effects + possible direct binding No binding No binding
a. All of these results were obtained at 37 °C in pH 7.4, 0.067 M phosphate buffer and are based on data from References [81, 86].
b. Sudlow sites I and II are also known as the warfarin site and indole site, respectively.
Figure 4. Chiral separation and analysis of tramadol and its major me-
tabolites using HPLC and a column containing immobilized AGP as the 
stationary phase. The results in (a) are for a blank human plasma sam-
ple. The results in (b) are for a plasma sample taken from a volunteer 
2.5 h after receiving a 100 mg dose of racemic tramadol. Symbols: en-
antiomers of tramadol, +(T) and −(T); enantiomers of the metabolite O-
desmethyltramadol, +(M1) and −(M1); enantiomers of the metabolite 
N-desmethyltramadol, +(M2) and −(M2); and internal standard (flucon-
azol), IS. Adapted with permission from Reference [96].
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binding of l-tryptophan and various indole compounds to this 
protein [102, 103, 104]. The same general method has been used 
to compare the binding of several sulfonylurea drugs with HSA 
and various preparations of glycated HSA [39, 105–110].
If a relatively large group of compounds is considered in a 
binding study, the results can be used to create a quantitative 
structure-retention (or reactivity) relationship (QSRR) to describe 
the site at which these agents are binding to a protein [111–114]. 
For instance, binding studies based on HPLC or CE using serum 
proteins can be used to mimic biological systems and to quickly 
study how changes in the structure of an applied drug or ana-
log will alter these interactions [115, 116]. This format has been 
used to build models that describe the binding of HSA with ben-
zodiazepines [117–119]. Such an approach has also been utilized 
to examine the binding of AGP with beta-adrenolytic drugs, an-
tihistamines, amino alcohols, cyclic vinca alkaloid analogs, and 
quinazolone derivatives [116, 120–125].
6. Interactions of proteins with xenobiotics and related 
metabolites
The term “xenobiotics” refers to chemicals that are produced syn-
thetically and that are not normally found in biological organisms 
[126]. Drugs represent one type of xenobiotic, but others include 
environmental pollutants and food additives [126–128]. When 
they enter the body, xenobiotics can be metabolized through var-
ious enzymatic processes. The resulting metabolites, in turn, can 
sometimes interact with proteins and compete for endogenous 
compounds for common binding agents [126, 129].
Several studies have examined the effects that xenobiotics and 
their metabolites may have on hormone–protein binding [127, 
130, 131]. For example, the effect of polybrominated diphenyl 
ethers (PBDEs) on the binding of thyroid hormones to serum pro-
teins has been examined [131]. It has been suggested in several 
studies that environmental exposure to PBDEs can result in de-
creased thyroid hormone concentrations in serum, leading to pos-
sible neurotoxicity and behavioral effects [131–133]. This effect 
may be linked to the fact that, when metabolized, PBDEs become 
hydroxylated and produce a chemical structure similar to that of 
T4 and its metabolites. It has been further found that PBDE me-
tabolites are able to bind to T4-binding proteins in serum, which 
could result in the displacement of thyroid hormones. One study 
examined the binding of transthyretin and TBG with fourteen hy-
droxylated PBDE compounds through various methods. A fluo-
rescence displacement assay indicated that hydroxylated PBDEs 
could compete with T4 for binding sites on transthyretin, while 
work with circular dichroism indicated that hydroxylated PBDEs 
could bind to the same sites as T4 on TBG and transthyretin [131]. 
Binding and competition with T4 has also been noted for some 
polychlorinated biphenyls (PCBs), dichlorodiphenyltrichloroeth-
ane (DDT), and related metabolites or compounds with respect to 
human thyroid receptor, TBG, and transthyretin [130].
Another report examined the effects for a number of xenobi-
otics and their metabolites on the binding of 17β-estradiol to the 
estrogen receptor and on the binding of 5α-dihydrotestosterone 
to the androgen receptor, androgen-binding protein, and SHBG 
[127]. Compounds that were tested included hexachlorocyclohex-
ane, DDT, methoxychlor, pentachlorophenol, and nonylphenol. It 
was found that some of these xenobiotics and metabolites could 
cause a significant decrease in the binding of 5α-hydrotestosterone 
or 17β-estradiol to their binding proteins. It was further found that 
binding by these xenobiotic agents could be selective for the steroid 
receptors and binding proteins that were tested [127].
Polyphenolic compounds are flavonoids that are often used 
as dietary supplements [128]. Ultrafiltration and CE were used 
to examine the binding of these compounds to the human se-
rum proteins HSA and AGP. Although similar in structure, these 
compounds did vary in their affinity toward HSA, with a high 
level of binding being observed for those compounds with hy-
drophobic properties and a carbonyl at position C(4) in their 
structure. It was further noted that these hydrophobic proper-
ties did not play a major role in the ability of polyphenolic com-
pounds to bind with AGP [128].
7. Variations in protein structure and binding due to meta-
bolic processes
Another way in which changes in metabolites may affect solute pro-
tein interactions is through changes that are created in the struc-
ture of the protein. In some cases, these changes may be a direct re-
sult of the modification of a protein by a metabolite (e.g., glycation, 
as discussed in the next section) [39, 80, 93, 134]. In others, this 
change may be a response to differences in a protein’s environment 
that are created as the metabolic profile is altered (e.g., as might oc-
cur through oxidation) [135, 136]. This section will discuss both 
types of effects using changes that have been observed in serum 
transport proteins and binding agents as examples.
7.1. Human serum albumin
One protein that has been found to be altered by some metabolic 
diseases is HSA. As has been indicated earlier, HSA is a serum pro-
tein that plays a fundamental role in the reversible binding and 
transport of metabolites, drugs and various endogenous ligands, 
such as fatty acids [65, 137]. HSA is normally found in blood at 
concentrations ranging from 30–50 g/L and accounts for approx-
imately 60% of the total serum protein content [65]. Binding to 
HSA is known to greatly influence the pharmacokinetics and ac-
tivity of many common drugs [49, 138–140]. In addition, HSA 
can increase the solubility of lipophilic drugs, sequester toxins, 
and act as an important antioxidant in plasma [49, 65].
Several past studies have noted that the chemical modifica-
tion of HSA can alter its binding to drugs, hormones and other 
solutes. For instance, the reaction of HSA with p-nitrophenyl ace-
tate, which is thought to mainly modify Tyr-411 at Sudlow site II, 
can change the binding of various solutes with this protein [141]. 
The modification of Trp-214 by o-nitrophenylsulphenyl chloride 
has been demonstrated to change the stereoselectivity and bind-
ing affinity of Sudlow site I of HSA [142]. Similar work has been 
presented that has examined the effects of modifying the lone 
free cysteine group on HSA by reacting this protein with ethac-
rynic acid [143, 144].
Diabetes is a metabolic disease in which the structure of HSA 
can be modified. This disease is actually a group of disorders that 
are characterized by abnormally high levels of blood glucose (i.e., 
hyperglycemia) that result from insulin deficiency and/or insu-
lin resistance [145]. Many of the long term complications of diabe-
tes, such as heart disease and nerve damage, are associated with the 
non-enzymatic glycation of proteins [145, 146]. Glycation starts 
with the nucleophilic attack of a reducing sugar (e.g., glucose) onto 
some of the primary amine groups on proteins to form a reversible 
Schiff base (see Figure 5). This intermediate can then slowly rear-
range to form a more stable Amadori product [145–147]. Oxidation 
of the Amadori products or free sugars can also generate reactive 
α-oxaloaldehydes that can react with both lysines and arginines on 
proteins to form advanced glycation end-products (AGEs) [147].
In recent years, it has been found that glycation can affect the 
binding of several endogenous and exogenous solutes with HSA. 
For example, l-tryptophan is an essential amino acid [148] and 
has been extensively used as a site-selective probe for Sudlow site 
II of glycated HSA and normal HSA [105, 106–108, 149]. Recent 
binding studies using glycated HSA with levels of modification 
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similar to those found in diabetes found an increase of 4.7–5.8-
fold in the affinity of l-tryptophan for this protein at 37 °C [106, 
149]. Sulfonylurea drugs are a group of anti-diabetic drugs that 
are used in the management of type 2 diabetes; these drugs are 
also highly bound to serum proteins such as HSA. Binding studies 
based on HPAC have found that glycation can affect the binding 
strength of these drugs to HSA, with both the degree of glycation 
and the specific type of drug influencing the size of the change 
[39, 105–110].
As indicated in the last section, fatty acids are the major en-
dogenous ligands of HSA and are also known to have many bind-
ing sites on this protein [75]. Reports that have examined the com-
bined effect of glycation and the presence of various fatty acids on 
the binding of sulfonylurea drugs to HSA have found that glycation 
increases the overall affinity of these drugs to HSA, while the addi-
tion of increasing amounts of fatty acids causes a decrease in affin-
ity [74, 76]. It has further been noted that glycation could produce 
changes of at least 3–5-fold in the affinities of some fatty acids at 
their sites of competition with sulfonylurea drugs when comparing 
the binding of these solutes to normal HSA [76].
Methylglyoxal is a highly reactive metabolite of glucose that 
has been implicated in several chronic diseases associated with di-
abetes [150, 151]. The elevated concentrations of methylglyoxal 
in diabetes patients can also lead to protein modification and the 
formation of AGEs through the reaction of methylglyoxal with ar-
ginine or lysine residues. A recent report using quantitative MS 
and multiple reaction monitoring found that a major site for mod-
ification by methylglyoxal on HSA occurs at Arg-257, which is lo-
cated in Sudlow site I. Molecular modeling conducted in the same 
study indicated that a decrease in binding by warfarin may oc-
cur due to these modifications when comparing glycated HSA and 
normal HSA [151].
7.2. Alpha1-acid glycoprotein
A second type of serum transport protein that can be affected by 
metabolic diseases is AGP. AGP is an acute-phase protein that is re-
sponsible for binding and delivering numerous basic and neutral 
drugs in the bloodstream [121]. The concentration of AGP in blood 
can vary over a wide range and is affected by systemic tissue injury, 
inflammation and infection. In addition, the glycosylation of AGP 
can be altered in some disease states, such as rheumatoid arthri-
tis, systemic lupus erythematosus and autoimmune thyroid disease 
[152]. These changes are important because they can also alter the 
binding of drugs to AGP. As an example, the affinity of disopyra-
mide for AGP has been found to be affected by the biantennary gly-
can structures for this protein [153, 154]. It has also been reported 
that genetic variants of AGP can have a significant effect on binding 
by chiral drugs such as disopyramide and warfarin [153, 155].
A number of reports have looked at how changes in AGP 
binding can affect parent drugs compared to their metabolites. 
One study evaluated the effect of AGP on lidocaine and its ac-
tive metabolites monoethylglycinexylidide and glycinexylidide 
during continuous epidural anesthesia in infants and young chil-
dren. The results indicated the AGP concentration in plasma 
could be used as an index to monitor and prevent the toxicity 
caused by the accumulation of monoethylglycinexylidide during 
the continuous administration of lidocaine [156]. Another re-
port looked at the concentrations of vecuronium and its metab-
olite 3-OH desacetylvecuronium in children who were receiving 
phenytoin or carbamazepine for chronic anticonvulsant therapy 
[157]. These last two drugs were of interest because many an-
ticonvulsant drugs have been shown to increase the concentra-
tion of AGP in plasma, which can then increase protein binding 
to cationic drugs and alter their distribution. It was found that 
the increase in AGP concentration associated with the anticon-
vulsant therapy did not significantly contribute to resistance to 
vecuronium [158].
7.3. Lipoproteins
Lipoproteins are another set of binding agents in serum that can 
be affected by metabolic diseases. Lipoproteins are macromolec-
ular complexes of proteins and lipids that transport hydropho-
bic lipids and related compounds, such as cholesterol and triglyc-
erides, throughout the body [158–161]. Lipoproteins are also 
known to interact with several basic and neutral hydrophobic 
drugs in blood [99, 162–172]. Examples of drugs that bind to li-
poproteins are propranolol and verapamil [37, 162–175].
Lipoprotein concentrations in blood can vary with different 
disease states. For example, the levels of low-density lipoprotein 
(LDL) in plasma can increase in diseases such as atherosclerosis 
and hyperlipidemia [176]. In addition to changes in the levels of 
lipoproteins in the circulation, metabolic diseases often result in 
modifications in lipoprotein structures. For instance, increased 
amounts of LDL that have been modified by AGEs are found in 
individuals with diabetics and non-diabetics with renal failure. 
Glycation of LDL may lead to the formation of foam cells and an 
increase in atherosclerosis. In addition, glycated LDL is more sus-
ceptible to further modifications due to oxidation [135].
The oxidation of lipoproteins occurs through free radicals, such 
as peroxyl radicals, which are released from cells and chemical re-
actions [136]. These radicals can react with lipoproteins, depleting 
the particle’s antioxidant defense and initiating oxidation of the 
lipid core. In the later stages of this process, the surface protein 
also becomes modified. The oxidation of lipoproteins, specifically 
LDL, leads to atherosclerosis [136]. In addition to the increased 
risk of atherosclerosis, oxidized lipoproteins may also impact the 
Figure 5. Reactions involved in the early stages of glycation of a protein, using human serum albumin (HSA) as an example [145].
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ability of the complexes to bind and carry basic and neutral drugs 
throughout the body [176].
The effects of LDL oxidation on drug binding have been eval-
uated by using CE and using verapamil and nilvadipine as models 
for basic and neutral drugs, respectively [176]. It was found that 
the affinity of these drugs increased with the amount of LDL oxi-
dation. In addition, the binding of verapamil was increased more 
than it was for nilvadipine, suggesting that basic drugs were more 
sensitive to oxidation effects. No stereoselective binding was de-
tected between LDL and these model drugs at any oxidation state 
[176]. However, other studies based on HPAC have noted differ-
ent binding for the chiral forms of some drugs to LDL [174, 175].
8. Conclusion
The field of metabolomics has seen great growth in recent years be-
cause of the wealth of information it can provide about biochemi-
cal pathways and processes. This review examined previous reports 
that have looked at the interactions of metabolites with proteins. 
The first topic discussed was an overview of techniques that have 
been used to characterize and study metabolite–protein binding. 
These methods have been used in vitro and in vivo to provide infor-
mation on the structures of metabolite–protein complexes and to 
examine the nature of metabolite–protein interactions. Computa-
tional studies using in silico tools have been used to provide addi-
tional data on metabolite–protein complexes and interactions.
This review next described numerous studies that have investi-
gated the binding of various types of small solutes and their me-
tabolites with proteins. This included work that has been carried 
out with hormones, fatty acids, drugs or other xenobiotics, and 
their metabolites with transport proteins and receptors. These 
examples have considered the structures of the resulting solute–
protein complexes, the nature of the binding sites, the strength of 
these interactions, the variations in these interactions with solute 
structure, and the kinetics of these reactions. Studies that have 
examined the effects of various metabolic processes on the struc-
ture and activities of proteins, and on the corresponding interac-
tions of solutes with these proteins, were also summarized.
Although most past work in metabolomics has been concerned 
with the structure and analysis of metabolites, research in metab-
olite–protein interactions is still a relatively new area. Based on 
the research that has already been carried out, it is already clear 
that data on metabolite–protein interactions can provide useful 
information on biological processes that involve hormones, drugs 
and other low mass solutes. It is further expected that this type 
of research will continue to grow in the future as metabolomics 
becomes more widely used in biomedical research, pharmaceutical 
science, and personalized medicine.
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